BSTC:OTC-BioSpecifics Technologies Corp (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 0.65B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware. As of December 1, 2020, BioSpecifics Technologies Corp. operates as a subsidiary of Endo International plc.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD232.05B 33.86 3.79
CMXHF CSL Limited

N/A

USD103.74B 43.22 29.42
CSLLY CSL Limited

N/A

USD103.74B 43.33 29.42
WXIBF WuXi Biologics (Cayman) Inc

N/A

USD64.56B 152.22 28.65
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD64.12B 151.57 28.65
GNMSF Genmab A/S

N/A

USD29.37B 74.77 8.17
UCBJY UCB SA

N/A

USD21.18B 19.78 14.67
UCBJF UCB SA

N/A

USD21.09B 19.61 14.67
SBHMY Sino Biopharmaceutical Limited

N/A

USD16.22B 10.75 2.15
SBMFF Sino Biopharmaceutical Limited

N/A

USD15.66B 10.39 2.15

ETFs Containing BSTC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.45% 52% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.45% 50% F 62% D-
Risk Return Profile  
Volatility (Standard Deviation) 26.27% 81% B- 60% D-
Risk Adjusted Return 32.19% 83% B 83% B
Market Capitalization 0.65B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 37.51 N/A N/A N/A N/A
Price/Book Ratio 4.81 N/A N/A N/A N/A
Price / Cash Flow Ratio 29.18 N/A N/A N/A N/A
EV/EBITDA 25.95 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 20.25% N/A N/A N/A N/A
Return on Assets 11.58% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.34 N/A N/A N/A N/A
Short Percent 1.19% N/A N/A N/A N/A
Beta 0.24 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike